The fundamental idea is being adaptive about how you allocate patients, but do so in a scientific way, and when there are multiple patients present. There has to be a scientific, what I call a policy, that the FDA is aware of, and is building the protocol. If eight out of 10 patients see success, and four out of 10 on B don't see success, then allocate one patient, move one patient from B to A. There has to be a scientific protocol that says, if this, this, this, and this happens, then do this. Wouldn't you want to allocate the patients on the bad arm to the better arm? The problem is that if you find out after a year that one arm is better than the other, or one treatment is better than the placebo, or the generic, you can't stop, because otherwise that you're violating the protocol. Now, let's say after a year you find that one treatment in particular is doing extremely well, which means great patient outcomes. As patients come in and are allocated one to the treatment arm and one to the placebos. What we are trying to do is to improve the way trials are conducted. I started getting interested in health care after I took a course in public policy. I find one of the strengths of University of Chicago is the interdisciplinary nature of the work, and then as long as you've got ideas people like to work together.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |